Dermatologic Therapy最新文献

筛选
英文 中文
Postoperative Intralesional Triamcinolone Acetonide for Keloid Recurrence Prevention: A Narrative Review of Protocols, Outcomes, and Comparative Therapies 术后病灶内曲安奈德预防瘢痕疙瘩复发:方案、结果和比较治疗的叙述性回顾
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-10-21 DOI: 10.1155/dth/4290127
Zina Khalid Mustafa, Abdulrahman Alghamdi, Feras M. Ghazawi
{"title":"Postoperative Intralesional Triamcinolone Acetonide for Keloid Recurrence Prevention: A Narrative Review of Protocols, Outcomes, and Comparative Therapies","authors":"Zina Khalid Mustafa,&nbsp;Abdulrahman Alghamdi,&nbsp;Feras M. Ghazawi","doi":"10.1155/dth/4290127","DOIUrl":"https://doi.org/10.1155/dth/4290127","url":null,"abstract":"<p>Keloids are benign fibroproliferative scars characterized by excessive collagen deposition and prolonged inflammation. Reported recurrence rates vary substantially across studies, while recurrence following excision alone has been reported to approach 100% in selected series. Intralesional triamcinolone acetonide (TAC) is widely used following excision, although protocols vary considerably and data comparing TAC with other adjuvant modalities remain inconsistent. This review evaluates current evidence on TAC as a postoperative therapy, compares its outcomes with alternatives such as radiotherapy and 5-fluorouracil (5-FU), and identifies gaps that limit development of standardized guidelines. The available literature supports postoperative intralesional TAC as a practical adjuvant for reducing keloid recurrence after excision; however, heterogeneity in study design, follow-up duration, and dosing protocols limits definitive recommendations and underscores the need for controlled comparative studies.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4290127","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149258378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aesthetic Medicine Procedures in Oncology Patients: A Safety-Based Clinical Framework for Restorative Oncodermatology 肿瘤患者的美容医学程序:恢复性皮肤肿瘤的安全临床框架
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-10-18 DOI: 10.1155/dth/5221506
Lidia Majewska, Karolina Dorosz, Jacek Kijowski
{"title":"Aesthetic Medicine Procedures in Oncology Patients: A Safety-Based Clinical Framework for Restorative Oncodermatology","authors":"Lidia Majewska,&nbsp;Karolina Dorosz,&nbsp;Jacek Kijowski","doi":"10.1155/dth/5221506","DOIUrl":"https://doi.org/10.1155/dth/5221506","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Increasing survival rates in oncology and the transformation of many cancers into chronic diseases have created new challenges for esthetic medicine. Dermatological sequelae of anticancer therapies—including volume loss, post-surgical scarring, radiation-induced telangiectasias, and pigmentation disorders—significantly impair quality of life and body image. The immunological specificity of oncology patients, however, requires a substantially modified approach to esthetic interventions, as articulated within the supportive and restorative oncodermatology frameworks.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To present a structured, literature-based framework for the safe application of esthetic medicine procedures in oncology patients, integrating immunological and clinical data with the principles of supportive oncodermatology.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Narrative review of clinical and immunological literature combined with expert synthesis. Procedures are stratified by safety profile for two patient populations: those undergoing active oncological treatment and long-term survivors.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Botulinum toxin, hyaluronic acid skin boosters, platelet-rich plasma (PRP), photobiomodulation (PBM), and nonablative laser techniques represent the lowest-risk interventions in this population. Immune checkpoint inhibitor (ICI) therapy substantially increases the risk of delayed granulomatous reactions at filler injection sites; emerging evidence further implicates BRAF and other tyrosine kinase inhibitors in late inflammatory filler reactions. Ablative lasers, deep chemical peels, and permanent fillers require deferral or are absolutely contraindicated. We propose a qualification approach based on “red flags” (absolute neutrophil count, platelet count, active infection, immunotherapy status, and radiotherapy timing).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Restorative oncodermatology, conceived within the broader supportive oncodermatology framework, treats esthetic interventions not as luxury procedures but as a potential component of survivorship care. Standardized patient qualification, interdisciplinary collaboration with oncologists, and evidence-informed procedure selection are essential. Given the limited prospective data, all recommendations presented here should be interpreted as the authors’ suggestions derived from the current literature and require ","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5221506","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149258183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Lifestyle Factors in Risk and Severity of Psoriasis in the Jordanian Population: A Multicentric Case–Control Study 生活方式因素在约旦人群牛皮癣风险和严重程度中的作用:一项多中心病例对照研究
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-10-18 DOI: 10.1155/dth/9883665
Rand Murshidi, Nour Shewaikani, Assem Al Refaei, Mahmoud Abdallat, Saed Samaro, Ola Noaman, Ayah Rashid, Awad Al-Tarawneh, Hanan Esmadi, Muayyad Murshidi, Salsabiela Bani Hamad
{"title":"The Role of Lifestyle Factors in Risk and Severity of Psoriasis in the Jordanian Population: A Multicentric Case–Control Study","authors":"Rand Murshidi,&nbsp;Nour Shewaikani,&nbsp;Assem Al Refaei,&nbsp;Mahmoud Abdallat,&nbsp;Saed Samaro,&nbsp;Ola Noaman,&nbsp;Ayah Rashid,&nbsp;Awad Al-Tarawneh,&nbsp;Hanan Esmadi,&nbsp;Muayyad Murshidi,&nbsp;Salsabiela Bani Hamad","doi":"10.1155/dth/9883665","DOIUrl":"https://doi.org/10.1155/dth/9883665","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Psoriasis prevalence varies globally and may be influenced by genetic and environmental factors. The association between physical activity, diet, fasting, and psoriasis risk, severity, and quality of life remains poorly understood.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study aimed to assess the relationship between physical activity, dietary habits, fasting, and psoriasis risk, severity, and quality of life.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A multicentric case–control study was conducted at Jordan University Hospital and Ministry of Health hospitals. Dietary habits, physical activity, disease severity, and quality of life were evaluated using validated questionnaires. A total of 478 participants, including 119 patients with psoriasis and 359 controls, with no significant differences in age or gender between groups, were included. Written consent was obtained, and the study was approved by the institutional review board.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;No significant differences in overall physical activity level, Mediterranean diet score, or usual fasting duration were observed between psoriasis patients and controls. However, selected Mediterranean diet components differed significantly between groups. Controls were more likely to report consuming fewer than two servings of red or processed meat per day and consuming one tablespoon or less of butter, margarine, or cream daily, whereas psoriasis cases more frequently reported sautéing with olive oil, garlic, onion, and tomato. Among psoriasis patients, PASI severity was positively correlated with DLQI scores (&lt;i&gt;r&lt;/i&gt; = 0.43, &lt;i&gt;p&lt;/i&gt; &lt; 0.001), and 44 patients had moderate-to-severe disease. Higher fruit intake was associated with lower PASI scores in unadjusted analysis (4.18 ± 3.25 vs. 6.37 ± 6.49; &lt;i&gt;p&lt;/i&gt; = 0.020). In multivariable regression, lifestyle variables were not independent predictors of PASI; DLQI was the only independent predictor of PASI severity.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In this multicentric Jordanian case–control study, overall Mediterranean diet adherence, physical activity, and fasting duration were not independently associated with psoriasis case status or PASI severity. Selected dietary components showed unadjusted associations with psoriasis case status or severity, particularly lower PASI scores among patients reporting higher fruit intake. Psoriasis severity was strongly associ","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9883665","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149258220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Evaluation of a 200-kDa Auto-Crosslinked Hyaluronic Acid Injectable in Facial Skin Quality: A Prospective Pilot Observational Study 注射200 kda自交联透明质酸对面部皮肤质量的临床评价:一项前瞻性先导观察研究
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-10-17 DOI: 10.1155/dth/5512277
Andrea Lazzarotto, Salvatore Piero Fundarò, Serena Gioana, Patrizia Piersini, Ilaria Proietti, Alberto Passi
{"title":"Clinical Evaluation of a 200-kDa Auto-Crosslinked Hyaluronic Acid Injectable in Facial Skin Quality: A Prospective Pilot Observational Study","authors":"Andrea Lazzarotto,&nbsp;Salvatore Piero Fundarò,&nbsp;Serena Gioana,&nbsp;Patrizia Piersini,&nbsp;Ilaria Proietti,&nbsp;Alberto Passi","doi":"10.1155/dth/5512277","DOIUrl":"https://doi.org/10.1155/dth/5512277","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan that plays a fundamental role in maintaining dermal hydration, elasticity, and turgor through its ability to retain large amounts of water and regulate the extracellular matrix (ECM). With advancing age, oxidative stress, ultraviolet exposure, and enzymatic degradation contribute to fragmentation and depolymerization of HA, resulting in loss of firmness, elasticity, and dermal density. Recent progress in biomaterial science has led to the development of HA with auto-crosslinked polymer (ACP) technology. This process creates a chemically crosslinked three-dimensional polymeric network without chemical residues, allowing the gradual release of bioactive 200-kDa low-molecular-weight HA fragments hypothesized to support fibroblast stimulation and collagen synthesis, based on preclinical evidence. This mechanism is hypothesized to support regenerative effects beyond simple volumetric correction.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To evaluate, in a pilot uncontrolled observational setting, physician-rated clinical outcomes following intradermal treatment with low-molecular-weight HA (200 kDa) stabilized with ACP technology in women with mild-to-moderate facial aging. No control group, placebo arm, objective biophysical measurements, or independent blinded evaluation were included.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Materials and Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Thirty healthy female patients underwent a minimum of three treatment sessions spaced 4 weeks apart (individual session counts are reported in Table 1) using a standardized vector injection technique (three vector technique) aligned with facial tension lines. Patients were initially classified according to aging severity using the Bazin Cheek Fold Score. Clinical outcomes were subsequently evaluated using the Global Aesthetic Improvement Scale (GAIS) and the Global Improvement Clinical Scale (GICS), which were applied exclusively after completion of the full treatment protocol to document physician-rated post-treatment scores. Statistical analyses included descriptive statistics, Welch’s &lt;i&gt;t&lt;/i&gt;-test, Hedges’ g for intergroup effect size, and Pearson’s correlation coefficient for exploratory analyses.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Posttreatment physician-rated assessments documented improvements in skin appearance across both aging groups. In the low-grade group, median posttreatment GAIS was 2 (range 1–3); in the high-grade group, median GAIS was 2 (range 1–4). Median GICS was 1 (range 1-2) in both ","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5512277","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shilajit Mouthwash as an Adjunct to Corticosteroid Therapy for Oral Lichen Planus: A Randomized Clinical Trial 希拉吉漱口水作为皮质类固醇治疗口腔扁平苔藓的辅助疗法:一项随机临床试验
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-10-16 DOI: 10.1155/dth/7960748
Aylar Afshari, Shohreh Alipour, Fahimeh Rezazadeh, Fatemeh Lavaee, Maryam Shahrokhi Sardoo
{"title":"Shilajit Mouthwash as an Adjunct to Corticosteroid Therapy for Oral Lichen Planus: A Randomized Clinical Trial","authors":"Aylar Afshari,&nbsp;Shohreh Alipour,&nbsp;Fahimeh Rezazadeh,&nbsp;Fatemeh Lavaee,&nbsp;Maryam Shahrokhi Sardoo","doi":"10.1155/dth/7960748","DOIUrl":"https://doi.org/10.1155/dth/7960748","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>Oral lichen planus (OLP) is a chronic inflammatory condition primarily managed with corticosteroids, which carry significant side effects. Shilajit, a traditional herbal–mineral remedy with anti-inflammatory and ulcer-healing properties, may offer an adjunct therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Experimental Procedure</h3>\u0000 \u0000 <p>This randomized, single-blind, placebo-controlled trial evaluated shilajit mouthwash in 51 OLP lesions (27 intervention, 24 control) alongside standard corticosteroid and nystatin therapy. Pain (visual analog scale, VAS), lesion severity (Thongprasom score), and lesion size were assessed over 60 days.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results and Conclusion</h3>\u0000 \u0000 <p>Both groups showed reduced pain and lesion severity, but the shilajit group exhibited a more sustained reduction in Thongprasom scores (<i>p</i> = 0.02). Lesion size reduction was not significantly different between groups, except for between Days 30 and 60. In this pilot study, shilajit mouthwash showed a more sustained reduction in Thongprasom-based lesion severity than corticosteroid alone, with minimal side effects; however, pain and lesion size reduction did not differ significantly between groups, and the Thongprasom finding should be interpreted cautiously given a baseline imbalance between groups. Larger trials with balanced baseline severity are needed before shilajit’s efficacy as an adjunct OLP treatment can be confirmed.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Iranian Registry of Clinical Trials: IRCT20120101008585N9</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7960748","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Multicenter Prospective Single-Arm Cohort Study on the Dynamic Attenuation of Therapeutic Effect of 308-nm Excimer Laser in the Treatment of Vitiligo Based on a Mixed-Effects Model and Time-Series Analysis 基于混合效应模型和时间序列分析的308 nm准分子激光治疗白癜风疗效动态衰减的多中心前瞻性单臂队列研究
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-10-13 DOI: 10.1155/dth/1873412
Yujin Sun, Shuxian Guo, Xuming Wang, Shuying Chang, Miao Miao, Guan Jiang
{"title":"A Multicenter Prospective Single-Arm Cohort Study on the Dynamic Attenuation of Therapeutic Effect of 308-nm Excimer Laser in the Treatment of Vitiligo Based on a Mixed-Effects Model and Time-Series Analysis","authors":"Yujin Sun,&nbsp;Shuxian Guo,&nbsp;Xuming Wang,&nbsp;Shuying Chang,&nbsp;Miao Miao,&nbsp;Guan Jiang","doi":"10.1155/dth/1873412","DOIUrl":"https://doi.org/10.1155/dth/1873412","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The purpose of this study was to investigate the attenuation of therapeutic efficacy of the 308-nm excimer laser in the treatment of vitiligo and to explore its temporal dynamics and underlying mechanisms through a mixed-effects model and time-series analysis, thereby providing a scientific basis for individualized treatment regimens.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design, Setting, and Participants</h3>\u0000 \u0000 <p>This was a multicenter, prospective cohort study comprising 170 patients with clinically stable vitiligo diagnosed between March and December 2024 at multiple participating dermatology clinics. Patients received 308-nm excimer laser therapy twice weekly. The Vitiligo Area Scoring Index (VASI) scores and repigmentation areas were recorded at baseline and at 2-week intervals over a 24-week period. A mixed-effects model combined with time-series analysis was utilized to calculate clinical efficacy, evaluate influencing factors, and analyze the dynamic trends of the treatment response.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During the initial phase of treatment, VASI scores decreased progressively as treatment advanced. However, between Weeks 21 and 24, the rate of VASI score reduction slowed considerably, with some patients exhibiting a therapeutic plateau or late-phase fluctuation (<i>p</i> &lt; 0.001), suggesting possible attenuation of the laser’s therapeutic effect.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The therapeutic efficacy of the 308-nm excimer laser in treating vitiligo undergoes dynamic attenuation and reaches a therapeutic plateau when continuous treatment extends to approximately 21–24 weeks.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Chinese Clinical Trial Registry: ChiCTR2600132228</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1873412","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodal Fusion for Acne Severity Assessment With Exploratory Landmark Prediction of a 12-Week Treatment Response: A Prospective Single-Center Cohort Study 痤疮严重程度评估的多模式融合与12周治疗反应的探索性里程碑预测:一项前瞻性单中心队列研究
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-10-12 DOI: 10.1155/dth/8579669
Xing Hu, Xiang Zhang, Jindong Zhang, Zainul Amiruddin Zakaria
{"title":"Multimodal Fusion for Acne Severity Assessment With Exploratory Landmark Prediction of a 12-Week Treatment Response: A Prospective Single-Center Cohort Study","authors":"Xing Hu,&nbsp;Xiang Zhang,&nbsp;Jindong Zhang,&nbsp;Zainul Amiruddin Zakaria","doi":"10.1155/dth/8579669","DOIUrl":"https://doi.org/10.1155/dth/8579669","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Acne is a common chronic inflammatory skin disease, and the subjectivity of severity assessment and uncertainty in short-term treatment-response prediction remain important clinical challenges. This study aimed to develop a multimodal fusion model integrating clinical features, radiomics features, deep learning image features, and attention-based fusion for acne severity assessment, with an exploratory leakage-free landmark prediction of a 12-week treatment response.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Materials and Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This prospective single-center cohort study enrolled 2186 patients with acne in the main cohort between January 2022 and January 2024. Of these, 2000 completed the 12-week follow-up and constituted the response-prediction cohort because the week-12 treatment-response outcome was available only for follow-up completers. The original fixed severity-development/test analysis was also constructed within the same 2000 completers to maintain one harmonized dual-task analytic dataset. However, week-12 follow-up is not intrinsically required for baseline severity assessment, and restriction of the severity analysis to completers may introduce attrition-related selection bias. Because the source-level baseline records of the 186 participants who did not complete follow-up could not be reliably retrieved and linked to the final analytic database, a valid post hoc attrition comparison and an all-enrolled baseline severity sensitivity analysis were not feasible. This limitation is now explicitly and prominently acknowledged in the Abstract, Methods, Results, Table note, Figure legend, and Discussion. A separately recruited single-center temporal validation cohort included 120 patients. Clinical data and standardized lesion images were collected at baseline and follow-up visits. Random forest, XGBoost, modified VGG16-based image feature extraction, and attention-based multimodal fusion were constructed for severity assessment. Fixed patient-level test-set reporting used one prediction per participant. To avoid temporal information leakage, a 12-week treatment-response prediction used cumulative landmark inputs available before the week-12 outcome: baseline-only, baseline plus week 4, and baseline plus week 4 and week 8. Baseline treatment modality was included as a prespecified categorical clinical covariate in treatment-adjusted response models, whereas week-12 compliance and week-12 features were excluded from prospective prediction inputs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Of 2186 enrolled participants, 2000 completed the 12-week follow-up (completion rate 91.5%). In the fixed patient-level held-ou","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8579669","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Baseline LDL Cholesterol and Week-16 Secukinumab Response in Moderate-to-Severe Plaque Psoriasis: A Retrospective Cohort Study 中重度斑块型银屑病患者基线LDL胆固醇与第16周Secukinumab应答之间的关联:一项回顾性队列研究
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-10-11 DOI: 10.1155/dth/5218624
Lihong Chen, Qi Yang, Hailun Wang, Szeman Cheung, Li Zhang, Xing Zou, Jiancheng Zhou, Feng Xue, Jie Zheng, Xia Li
{"title":"Association Between Baseline LDL Cholesterol and Week-16 Secukinumab Response in Moderate-to-Severe Plaque Psoriasis: A Retrospective Cohort Study","authors":"Lihong Chen,&nbsp;Qi Yang,&nbsp;Hailun Wang,&nbsp;Szeman Cheung,&nbsp;Li Zhang,&nbsp;Xing Zou,&nbsp;Jiancheng Zhou,&nbsp;Feng Xue,&nbsp;Jie Zheng,&nbsp;Xia Li","doi":"10.1155/dth/5218624","DOIUrl":"https://doi.org/10.1155/dth/5218624","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Psoriasis is a systemic inflammatory disease frequently accompanied by cardiometabolic comorbidities. Whether baseline lipid status influences clinical response to interleukin-17A blockade remains insufficiently defined.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To evaluate the association between baseline low-density lipoprotein cholesterol (LDL) and week-16 clinical response to secukinumab in patients with moderate-to-severe plaque psoriasis and to describe outcomes under 150-mg and 300-mg dosing regimens in real-world practice.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We performed a single-center retrospective cohort study including 325 patients with moderate-to-severe plaque psoriasis who received secukinumab for at least 16 weeks.&lt;/p&gt;\u0000 \u0000 &lt;p&gt;Patients received either 150 mg or 300 mg secukinumab at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. The primary outcome was achievement of at least 75% improvement in Psoriasis Area and Severity Index (PASI75) at week 16. Propensity score weighting was used to reduce baseline imbalance between dosing groups. The primary association was estimated using multivariable logistic regression with baseline LDL modeled continuously and adjustment for multiple factors. Missing LDL was evaluated using measured-versus-missing comparisons and multiple imputation as a sensitivity analysis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;After inverse probability weighting, baseline demographic and disease severity variables were generally balanced between dose groups, although residual imbalance in selected laboratory variables remained. Week-16 PASI75 response did not differ significantly between the 150-mg and 300-mg groups after adjustment, while early PASI90 response was more frequent in the 300-mg group and week-16 PASI100 response was more frequent in the 150-mg group. Baseline LDL was inversely associated with PASI75 response at week 16 (ORs per 1 mmol/L increase, 0.696, and 95% CI: 0.497–0.976), and further multiple imputation as a sensitivity analysis confirmed the adjusted OR was 0.718 (95% CI: 0.516–0.999, &lt;i&gt;p&lt;/i&gt; = 0.049). Patients with low LDL had a higher PASI75 response rate than those with high LDL (85.2% vs 66.7%). In the 300-mg subgroup, high LDL was associated with lower PASI75 and PASI90 response rates. Secukinumab reduced selected inflammatory and metabolic biomarkers, including CRP, ESR, SCC, glucose, and triglycerides, but LDL and HDL did not show significant improvement over 16 weeks.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 ","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5218624","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dermatology in the Age of Obesity: The Good, the Bad, and the Ugly of GLP-1 Receptor Agonists and Tirzepatide 肥胖时代的皮肤病学:GLP-1受体激动剂和替西肽的好、坏和丑
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-10-08 DOI: 10.1155/dth/5742100
Sebastián Guerrero-López, Sara Cataño-Restrepo, Sofía Pérez-Lalinde, Daniela Chaparro-Reyes
{"title":"Dermatology in the Age of Obesity: The Good, the Bad, and the Ugly of GLP-1 Receptor Agonists and Tirzepatide","authors":"Sebastián Guerrero-López,&nbsp;Sara Cataño-Restrepo,&nbsp;Sofía Pérez-Lalinde,&nbsp;Daniela Chaparro-Reyes","doi":"10.1155/dth/5742100","DOIUrl":"https://doi.org/10.1155/dth/5742100","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide have moved rapidly from diabetes management into widespread obesity treatment, drawing growing interest in their dermatologic implications. Given the close relationship between obesity, insulin resistance, systemic inflammation, nutritional alterations, and cutaneous homeostasis, these agents may influence the skin through both beneficial and adverse mechanisms.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To review and critically evaluate the current literature regarding the dermatologic effects of GLP-1RAs and tirzepatide, with emphasis on differentiating direct pharmacologic effects, indirect weight loss–mediated effects via metabolic changes, and multifactorial and uncertain mechanisms.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A focused narrative review was conducted in accordance with the principles of the Scale for the Assessment of Narrative Review Articles (SANRA) using targeted searches in PubMed/MEDLINE, Scopus, and Embase through April 2026. Preference was given to systematic reviews, meta-analyses, randomized clinical trials, multicenter observational studies, translational mechanistic research, and pharmacovigilance reports. Selected case reports were incorporated when considered clinically relevant. Findings were analyzed according to study quality, biological plausibility, consistency among different evidence sources, and applicability to dermatologic practice.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Among the potential beneficial dermatologic effects, psoriasis showed the most promising evidence, with meta-analytic studies reporting reductions in Psoriasis Area and Severity Index scores and achievement of PASI 75 in a proportion of patients. Hidradenitis suppurativa also showed improvement in several observational studies, including reductions in disease activity, pain, and flare frequency, although the independent contribution of weight loss and metabolic improvement remains difficult to separate. Additionally, experimental data suggest possible benefits in wound repair through anti-inflammatory and angiogenic modulation, but clinical evidence in dermatology is still scarce. Hair loss emerged as the most consistently reported adverse cutaneous event; pharmacovigilance analyses and pooled clinical trial data suggest an increased risk, most commonly compatible with telogen effluvium associated with rapid weight reduction and metabolic stress. Injection-site reactions and mild hypersensitivity phenomena are relatively frequent","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5742100","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Guselkumab on Serum Uric Acid Levels in Patients With Psoriasis: A Retrospective Cohort Study Guselkumab对银屑病患者血清尿酸水平的影响:一项回顾性队列研究
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-10-05 DOI: 10.1155/dth/1440163
Chao Wu, Dian-Mo Li, Xin-Yuan Zhang, Dan Shu, Wen-Ming Wang, Hai-Meng Wang, Yi Zhao, Chun-Xia He, Hong-Zhong Jin
{"title":"Effect of Guselkumab on Serum Uric Acid Levels in Patients With Psoriasis: A Retrospective Cohort Study","authors":"Chao Wu,&nbsp;Dian-Mo Li,&nbsp;Xin-Yuan Zhang,&nbsp;Dan Shu,&nbsp;Wen-Ming Wang,&nbsp;Hai-Meng Wang,&nbsp;Yi Zhao,&nbsp;Chun-Xia He,&nbsp;Hong-Zhong Jin","doi":"10.1155/dth/1440163","DOIUrl":"https://doi.org/10.1155/dth/1440163","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hyperuricemia (HUA) is common in psoriasis, but the effect of selective interleukin (IL)-23 inhibition on serum uric acid (UA) is inconsistent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this two-center retrospective cohort, 228 adults with chronic plaque psoriasis received guselkumab for 52 weeks. The primary outcome was the change in UA (ΔUA). Secondary outcomes included HUA resolution, new-onset HUA, predictors of baseline HUA and HUA resolution, and the association of ΔUA with Psoriasis Area and Severity Index (PASI) response and change in high-sensitivity C-reactive protein (ΔhsCRP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At baseline, 92 patients (40.4%) had HUA. UA decreased in the overall cohort (median ΔUA −10.5 μmol/L; bootstrap 95% CI −19.0 to −3.0; <i>p</i> &lt; 0.001), with the largest reduction among baseline HUA patients (median −35.5 μmol/L; 95% CI −53.5 to −17.0), 32.6% of whom achieved HUA resolution; cohort HUA prevalence fell from 40.4% to 33.3% (McNemar <i>p</i> = 0.023). 10.3% of patients with normal baseline UA developed new-onset HUA. ΔUA correlated weakly with ΔhsCRP but not with PASI change. Male sex and higher BMI independently predicted baseline HUA; lower baseline total cholesterol and higher baseline PASI independently predicted HUA resolution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Guselkumab was associated with a statistically significant but modest UA reduction, which was largest in patients with HUA and was independent of skin clearance over 52 weeks, suggesting an ancillary metabolic effect of IL-23 inhibition that warrants prospective confirmation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1440163","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149145864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书